Megaloblastic Anemia MCQ — NEET PG Practice Question | NEETPGAI
Megaloblastic Anemia
hard
microscope Pathology
A 65-year-old man on methotrexate for rheumatoid arthritis develops macrocytic anemia with megaloblastic changes on bone marrow. B12 and folate levels are low-normal. Which is the drug of choice to prevent and treat methotrexate-induced megaloblastic anemia?
A. Folic acid 1 mg orally daily
B. Folinic acid (leucovorin) 5 mg orally daily on non-methotrexate days
C. Methylfolate 5 mg orally daily
D. Cyanocobalamin 1000 mcg intramuscularly monthly
Methotrexate (MTX) inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate (THF). This causes functional folate deficiency and megaloblastic anemia, even when serum folate is low-normal.
Folinic acid (5-formyl-THF, leucovorin) is the drug of choice for MTX-induced megaloblastic anemia because it bypasses the DHFR block and directly replenishes the THF pool.
High-YieldNEET PG
Standard dosing:
5 mg orally once daily on non-MTX days (e.g., if MTX given weekly, give folinic acid on days 2–7)
Alternative: 5 mg twice weekly on non-MTX days
This prevents and treats MTX-induced folate deficiency
Why Folinic Acid (Not Folic Acid) in MTX Therapy?
Loading diagram...
Table
Feature
Folic Acid
Folinic Acid (Leucovorin)
Requires DHFR?
Yes
No
Effective in MTX therapy?
No (DHFR blocked)
Yes (bypasses block)
First-line for MTX prevention
No
Yes
Cost
Lower
Higher
Onset of action
Slow
Rapid
Clinical Pearl
Folic acid is ineffective in MTX-induced deficiency because MTX blocks its conversion to THF. Folinic acid works because it is already in the active form (5-formyl-THF) and does not require DHFR.
Mnemonic
FOLINIC = Folinic for MTX — Folinic acid is the rescue agent for methotrexate toxicity because it bypasses the DHFR block.
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.